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Abstract 
 
Primary malignant melanoma of sinonasal tract (PMMST) is a rare but severe form of 
melanoma. We retrospectively analyzed 17 cases and focused on the histological presentation, 
the expression of c-Kit, EGFR, cyclin-D1/Bcl-1, PS100 and HMB45 and searched for BRAF, 
NRAS and KIT mutations that are known to be associated with melanoma subtypes, together 
with amplifications of KIT, CCND1, CDK4, MDM2 and MITF using quantitative PCR. In the 
majority of cases (78%), an in situ component was evidenced. Invasive components were 
composed of diffuse areas of rhabdoid, epithelioid or spindle cells, and in most cases lacked 
inflammatory reaction, suggesting that an immune escape phenomenon probably develops 
when the disease progresses. EGFR was rarely and weakly expressed in the in situ component 
of 2 cases. None of the investigated case showed BRAFV600E, but one had a D594G 
mutation. NRAS mutations in exon 2 (G12D or G12A) were found in 3 cases (18%) and a KIT 
mutation in exon 11 (L576P) in one, while C-Kit was expressed at the protein level in half 
cases. Amplifications of CCND1 were evidenced in 5 cases, confirmed in 3 by FISH studies, 
but this was not always correlated with protein expression, found in 8 patients (62.5%), 3 
having no significant amplification. In conclusion, PMMST are not associated with 
BRAFV600E mutations. Instead, NRAS or KIT mutations and CCND1 amplification can be 
found in a proportion of cases, suggesting that PMMST are heterogeneous at the molecular 
level and should not be sensitive to therapeutic approaches aiming at BRAF. 
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Introduction 
Primary melanoma of sinonasal tract (PMST) is a rare melanoma variant that primarily 
develops in the nasal cavity, nasopharynx or paranasal tissue and can thereafter spread in 
several compartments. Their histological and phenotypical characteristics have been well 
described, especially in the large series from Thompson and colleagues[1], but only few series 
of cases were published to date. The patients most often present with epistaxis and the tumor 
can show a broad spectrum of cytologic aspects and architectural patterns, so that the 
diagnosis most often relies on the immunohistochemical markers, with a similar sensitivity 
and specificity to cutaneous and other non cutaneous melanomas[1]. The prognosis is poor, 
with many patients having local recurrence and a high mortality rate, despite surgery and 
radiation and/or chemotherapy, with a mean 5 years overall survival of 42-43%[1, 2]. The 
prognosis depends on the level of local invasion, and, due to the particular anatomic 
localization, a specific adapted staging system was proposed[1, 2], including one that fits into 
the international TNM staging system requirements[1]. The oncogenic events responsible for 
melanoma development, in both cutaneous and non cutaneous melanomas, are better 
characterized. Besides genes associated with familial melanomas, such as CDKN2A, various 
genetic aberrations occur at the somatic level, especially involving receptors or downstream 
partners involved in the MAPK signalling pathway. Among them KIT, RAS and BRAF are 
found to be mutated at various frequencies and have been the most studied, while other genes 
were found to be mutated in more sporadic studies. These include amplifications of CCND1, 
CDK4 and MITF, or suppressor genes abnormalities (PTEN, APAF1 and TP53). BRAF 
mutations are found in about 50% of cutaneous melanomas, with the V600E substitution 
being the most frequent aberration, and are very rare in mucosal melanomas.[3] BRAF and 
NRAS are two upstream members of the MAPK pathway, which are activated by tyrosine 
kinase receptors, such as c-Kit. The KIT gene, mapped to 4q12, encodes an oncogenic 
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transmembrane receptor tyrosine kinase, c-Kit, whose ligand is stem cell factor. C-Kit plays 
an important role in melanocyte migration, development, differentiation and tumorigenesis. 
KIT mutation are found in up to 20% of mucosal melanomas, a lower proportion of acral 
melanomas, and appears to be very rare in cutaneous nonacral tumors.[3]. Interestingly, it was 
recently shown that the percentage of c-Kit positive neoplastic cells in acral melanoma was a 
predictive factor of the mutational status.[4] The finding of these genetic aberrations recently 
allowed the setting of targeted therapies directed against these oncogenes or their signaling 
pathways in patients with advanced stages[5, 6] Although none has dramatically improved the 
management of advanced stage melanoma, encouraging results were actually obtained. While 
PMMST are often aggressive and locally advanced melanomas, only one recent study has 
focused on the oncogenic mutations associated with this melanoma subtype, showing that a 
proportion of cases are associated with NRAS and KIT mutations but not with CCND1 
amplification. To address this issue, we report here 17 additional cases of PMMST with 
immunohistochemical and molecular genetic studies focusing on KIT, BRAF, NRAS and 
CCND1. 
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Material and methods 
 
Patients and tissue samples 
 A total of 17 cases of PMMST were retrospectively and prospectively included. The 
cases were retrieved from department of pathology of the centre hospitalier inter-communal 
de Créteil and Henri Mondor hospital, between 1995 and 2012. The demographic symptoms 
and clinical features at presentation (gender, age epistaxis, nasal obstruction, nasal mass, 
polyp and pain), location of the tumors (nasal cavity, septum, frontal, ethmoidal, maxillary 
sinus), together with the personal and familial past medical history were reviewed in all cases.  
Pathologic study 
 The following macroscopic features were recorded: tumor size, color, necrosis and 
hemorrhage. Hematoxylin and eosin stained slides were reviewed and the following histologic 
parameters were recorded, according to the previously published series from Thompson et 
al.[1]: surface epithelium (present or absent), in situ component, architectural pattern of 
growth (solid, epithelioid, meningothelial, hemangiopericytoma-like, peritheliomatous, 
papillary, storiform), cell type (undifferentiated, epithelioid, small cell, plasmacytoid, 
rhabdoid, giant cells), melanin pigment (present or absent), inflammatory response (present or 
absent), topography of inflammatory response (inside or outside of tumor), index of mitotic 
figures, perineural invasion and vascular invasion. Tumor necrosis was noted as : 0: absent, 1 
: <5%, 2 : <50%, 3 : >50%.  0 : absent, 1 : low, 2 : moderated, 3 :important, The topography 
(around the in situ and/or within the invasive neoplastic components) of the inflammatory 
reaction was evaluated together with intensity, quantified as follows : 0 : absent, 1 : low 
(sparsed cells), 2 : moderated (grouped cells), 3 : important (sheets of inflammatory cells), 
Immunohistochemistry 
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 For immunohistochemistry, we used the Bond-Max device (Bond, Leica Menarini). 
The staining was done after antigen retrieval by heat with appropriate buffer with peroxydase 
and diaminobenzidine. The deparaffinized sections were stained for CKit (Dako; clone 
A4502; 1:900 dilution ), EGFR (Zymed; clone 28-0005; 1:200 dilution), PS100 (Dako; clone 
Z311; 1:3000 dilution), HMB45 (Dako; clone M0634; 1/100 dilution), Cyclin D1/BCL1 
(Microm; clone SP4; 1:25 dilution). The expression of each marker was investigated in the 
two in situ and invasive melanoma components, when applicable. We assessed both the 
proportion of stained cells on a scale of 0 to 10 (0, 10% ... 90%, 100%) and the staining 
intensity (low, moderate, high). 
 
Interphase fluorescence in situ hybridization (FISH) analysis 
 FISH analysis was performed on 3M TMA tissue sections using split signal FISH 
DNA probes for CCND1/11q13 (probe Y5414, Dako, SA, Glostrup, Denmark) according to 
the manufacturer’s recommendations (www.euro-fish.org). Slides were analysed with a Zeiss 
AxioImager Z1 fluorescence microscope equipped with microscope-specific double filters 
(XF53, Omega Optical, Brattleboro, VT, USA) suitable for the fluorescein isothiocyanate and 
Texas Red labelled split-signal probes. Slides were analysed independently by two scorers 
(MB, CCB) with a 100x oil immersion objective. For archiving, images were captured with 
40x objective using a Hamamatsu digital camera attached to the fluorescence microscope and 
Visilog software (NOESIS, Les Ulis, France). 
Amplification was defined as the presence of at least 6 fusion signals per nuclei.  
 
Molecular studies 
 Molecular studies were performed in 15 cases. Genomic DNA was extracted fom five 
10M sections of the paraffin blocks, by using the QIAamp DNA FFPE kit (Qiagen). 
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Sequence analyses were done on the BRAF exons 11 and 15, NRAS exons 2 et 3 and KIT 
exons 11, 13, 17 and 18. Amplified products were obtained by PCR with specific primers 
(Table 1). The amplification procedure was done using the Taq polymerase manufacturer’s 
instructions (Invitrogen). To avoid DNA amplification inhibition by melanin, 10 g bovin 
serum albumin were added to the PCR mixes. PCR products were purified after migration on 
an agarose gel using the illustra GFX PCR DNA and Gel Band Purification Kit (GE 
Healthcare). The PCR purified products were then sequenced using the BigDye Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems) following the manufacturer's instructions. 
 Gene copy number was assessed by quantitative real-time PCR by comparison with 
GAPDH or Actin using primers described in Table 1. PCR reactions were done in duplicate 
using the Power SYBR Green PCR Master Mix kit (Applied Biosystems) following the 
manufacturer's instructions. Relative copy numbers were calculated using the ΔΔCt method, 
where Ct is the threshold cycle for amplification. For each sample, ΔCt for the gene of interest 
versus GAPDH or Actin was calculated as ΔCt = Ct(gene of interest) - Ct(GAPDH/Actin). 
The ΔCt value for each experimental test sample was calibrated to a reference pool of 
genomic DNA prepared from primary cells. Relative DNA copy number was calculated using 
the formula 2
- ΔΔCt
. Relative copy numbers were converted to absolute copy numbers by 
assigning a value of 2 (diploid) to the reference pool and multiplying the relative copy number 
of test samples by a factor of 2. The threshold for increased copy number was set to 5 copies 
of the gene of interest relative to GAPDH/Actin. 
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Results 
 
Clinical features 
 The patients included 12 women and 5 men (sex ratio = 0.42), who ranged in age from 
46 to 97 years. Most patients (13/15, 87%) had epistaxis. Three (3/15) complained of nasal 
obstruction. Periorbital headache and earache were reported in 2 cases. One patient presented 
anosmia without epistaxis (Table 2). A history of cutaneous melanoma was found in a case 
that reported the removal of 2 cutaneous melanomas, one at the right forearm, and another at 
the left cheek without available pathologic reports. No patients in this series had a dysplastic 
nevus syndrome or a xeroderma pigmentosum. Tumours were located in the nasal cavity in 
65% of cases (11/17), sinus without nasal involvement in 18% (3/17). A local extension to the 
orbit was found in 2 cases. The tumor prolapsed in the nasopharynx in one case. Tumor size 
ranged between 1 and 5.5 cm with a mean of 3.25 cm. 
 
Histologic features 
 The majority of samples was submitted in multiple fragments and were blackish or 
brownish. In one case the tumor was whitish translucent. Four cases presented as a polypoid 
tumor, while most cases were ill defined masses. Most cases showed, at least partially, a solid 
architecture (16/17, 94%), while a pure peritheliomatous (n=2) or meningothelial (n=1) 
architecture were less frequent (Table 2). The tumor cells were often cytologically 
undifferentiated (7/17). One cases associated undifferentiated and spindle cells components 
(2/17) or mixed rhabdoid and giant cells (2/17). Cases with plasmacytoid (1/17) and 
epithelioid cells (1/17) were rare. Mitotic figures were identified in all cases with a mean of 
18 mitotic figures per 10 high power fields (range 4-36). An in situ component was observed 
in 11 cases (78%). One case that presented as a polyp displayed only an in situ component. 
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Inflammatory cells were present in only 7 cases. Lymphoid cells were predominant beneath 
the in situ component. A stroma reaction was absent. Only 4 cases showed fibrosis and an 
ulceration was seen in 9 cases. We identified metaplastic bone within the tumors in 3 cases. 
Melanin Pigment was revealed in the neoplastic tumor cells in 8 cases, and was pronounced 
beneath the in situ components in the form of melanophages aggregates.  
 
 
Immunohistochemical analyses 
 S100 protein was expressed in most cases (14/17, 82,6%), but the proportion of 
stained cells, as well as the staining intensity greatly varied from on case to another, ranging 
from a low expression in about 20% of cells to a strong expression in the majority of 
neoplastic cells. HMB45 and Melan-A (Figures 1A and 1B) were expressed in all cases, but 
the proportion of positive cells also varied a lot, from 5% to 100% of cases. EGFR was not 
expressed in most cases, except for one case in the invasive component, with all neoplastic 
cells being positive. In two cases, the in situ component appeared to be weakly EGFR 
positive, with 10% to 50% of positive cells, but neoplastic stained cells were often difficult to 
distinguish from normal epithelial cells. c-Kit was found to be expressed in 8 samples (47%) 
in the invasive components (Figure 1D). In most of these samples, the staining intensity was 
weak or moderate (6/8, 75%). The in situ neoplastic cells expressed c-Kit in 10 cases (Figure 
1C). Four of these samples did not show c-Kit protein expression within the invasive 
components, while two samples with a c-Kit
+
 invasive components had no positive cells in 
situ. Cyclin D1 was found to be expressed in 10 samples in the invasive component (10/16, 
62.5%, Figures 1E and 1F), with a variable proportion of stained cells, ranging from 10% to 
80%. The staining intensity appeared to be strong or at least moderate in most samples (7/10, 
70%). In most of these cases, we also evidenced Cyclin D1 expression in the in situ 
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components, except for two samples, that both showed a weak expression in a minority of 
tumoral cells in the invasive component (10%) 
 
Molecular and FISH studies 
 MDM2 gene copy numbers was within normal range in all samples using quantitative 
PCR, while KIT, MITF and CDK4 amplifications could be demonstrated in one case each. An 
amplification of CCND1 could be demonstrated in 5 samples (31%), 3 by both qPCR and 
FISH, 2 by qPCR alone. As seen in Figure 2, cases displaying CCND1 amplification showed 
a high copy number of the gene in neoplastic cells nuclei, with more than 10 to innumerable 
signals per nuclei (Figure 2A and B).  
 Regarding sequence analyzes, only one case had a BRAF mutation, yielding a D594G 
substitution, while the classical V600E was never found.  G12D (n=2) or G12A (n=1) NRAS 
mutations in exon 2 were demonstrated in 3 cases (18%). Finally only one sample was 
associated with a KIT mutation in exon 11, leading to a replacement in position 576 of a 
leucine by a proline (L576P) (Figure 3 and table 3). 
 All the genetic aberrations described above appeared to be mutually exclusive, except 
for cases 9 and 15. In case 9, several genes were found to be amplified (CCND1, CDK4 and 
MITF), while case 15 showed both a G12D NRAS mutation and an amplification of the 
CCND1 gene. 
 
Molecular and phenotypic correlations. 
 At the protein level using immunohistochemistry, c-Kit was found to be expressed in 
about half cases (8/17), with a variable proportion of stained cells and various staining 
intensities. Interestingly, only 3 showed a high proportion (about 50% in all three) of stained 
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cell and among them, 2 had KIT gene abnormalities, with one being amplified and the other 
showing an activating mutation (Table 4). 
 By contrast, no strict correlation between CCND1 gene amplification and cycline D1 
protein expression was observed, as only 2 of the amplified cases displayed a high proportion 
of stained cells, whereas 3 with no gene amplification were associated with an important 
proportion of stained cells (Table 4). 
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Discussion 
 
 Primary malignant melanoma of sinonasal tract (PMMST) is a rare form of melanoma 
with a poor prognosis. We here report a series of 17 cases in which we focused on oncogene 
mutations and amplifications. Clinical-pathological findings were similar to that reported in 
the large series of cases from Thompson et al. [1] In our series, we found that most cases were 
associated with an in situ component (78%), suggesting that PMMST follows a two step 
invasion process, with an initial intra-mucosal development, similar to skin melanomas. The 
finding of only an in situ melanoma in a patient that consulted for nasal obstruction due to a 
nasal polyp supports this hypothesis. Interestingly, the situ components appeared to be more 
pigmented than the invasive components, which may suggest that melanoma progression is 
associated with a loss in melanocytic differentiation. While only few cases showed a 
significant inflammatory infiltrate in the invasive components, in situ lesions were always 
associated with a coarse infiltrate. This may suggest that tumor escape mechanisms may 
develop and be associated with melanoma progression. 
 An understanding of the genetic basis of cutaneous melanoma has recently shed light 
on the mechanisms of melanoma genesis. Especially, somatic mutations of the BRAF, NRAS, 
HRAS and GNAQ genes have been shown to be associated with variable frequencies with 
melanoma subtypes. Due to anatomic complexity of the sinonasal tract, leading to difficult 
surgical removal of the primary tumor, and because they are often diagnosed at advanced 
stages and follow an aggressive course, PMMST are good candidates for additional 
treatments.  To the best of our knowledge, however, only one recently published study 
focused on PMMST. [7] Interestingly, among the 32 cases recently published in this series, 
none was associated with the BRAFV600E mutation, while a D594G could be demonstrated 
in one sample, as in our series. The BRAFD594G mutation appears to be rare, and actually, to 
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the best of our knowledge, was only described in a melanoma cell line.[8] Compared to the 
classical V600E, this mutation appears to be a low activity mutant and to signal through 
CRAF on the MAPK pathway. We found NRAS mutations in 18% (3/17) of our sample, a 
frequency similar to that previously reported.[9] However, the NRAS mutation spectrum in 
PMMST is different from the one found in other melanoma. Indeed, NRAS mutations in 
cutaneous melanoma are usually localized at codon Q61 (88%) and rarely at codons G12 
(6%) and G13 (6%).[10] The high frequency of NRAS mutations at codon 61 in melanoma has 
been linked to the presence of mutagenic UV-induced DNA photoproducts, which have been 
found preferentially around codon 61 and rarely around codon 12 in UV-irradiated human 
cells.[11] Interestingly, the NRAS mutations we found in PMMST were all located at codon 
G12 and in a recent analysis of sinonasal melanoma, Turri-Zanoni M et al. also found NRAS 
mutations at codons G12 and G13.[7] Therefore, the NRAS mutation spectrum found in nasal 
melanoma is different from the one found in other melanoma but strikingly closer to the one 
described in tumors derived from hematopoietic and lymphoid tissue. This result suggests that 
the molecular mechanisms involved in NRAS mutation in PMMST are different from other 
melanomas, and, as expected in this anatomic localization, are unrelated to UV exposure. 
RAS acts as a MAPK signaling protein, upstream of RAF. Although no specific therapies 
aiming at RAS are available to date, it is known that inhibition of NRAS should aim both 
BRAF and CRAF or BRAF and PIK3CA.[12]The interaction between the MAPK pathway is 
actually complex. It has been shown for instance that oncogenic RAS inhibits NRAS-BRAF 
interaction, leading to CRAF reactivation ad cAMP phosphodiesterase hyperactivity.[13] 
 KIT mutations were previously shown to be preferentially associated with mucosal 
melanomas. They are expected at a 9-10% rate and have been shown to represent an adverse 
prognostic factor.[14] We actually found only one sample with a KIT mutation, while KIT 
mutations were found in 4 out of 32 samples in the series from Turri-Zanoni et al. Our case 
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had a L576P mutation in exon 11, which is the most frequent KIT mutation in melanomas. We 
also found significant c-Kit protein expression in a subset of cases (62.5%), including the one 
associated with an activating mutation of the gene, a percentage however lower than the 97% 
of cases showing KIT protein expression .in the study from Turri-Zanoni M et al. These 
results suggest that c-Kit is involved in PMMST cells survival and/or proliferation, but may 
not be as important as in other mucosal melanoma subtypes. Overall, we did not find a 
significant correlation between c-Kit expression and KIT mutation status, as shown for 
melanoma of mucous membranes from other sites,[4] further suggesting the PMMST have 
distinctive oncogenic properties. 
 We found CCND1 amplification by qPCR in a significant subset of our cases (37,5%), 
and confirmed it in some samples by FISH analysis. In keeping with this observation, many 
cases showed a nuclear expression of cyclin D1, although no strict correlation could be 
observed between CCND1 amplification and cyclin D1 protein expression, suggesting that 
cyclin D1 protein expression is regulated at many levels in melanoma. The reason why we 
found more frequent CCND1 amplification than Turri-Zanoni et al in their recent study is 
unclear, but may be due to the different probe we used or the high sensitivity of qPCR. 
Nevertheless, our data suggest that CCND1 is an important oncogene in sinonasal melanoma 
and that these tumors could be amenable for therapy targeting the cyclinD1/CDK4 pathway. 
 In conclusion, we confirm recently published results showing that a proportion of 
PMMST are associated with NRAS and less frequently KIT activating mutation, while the 
classical BRAFV600E is absent. In our series, c-Kit was expressed at the protein level in only 
half cases, and was not an indicator of KIT mutation, since only one case had a KIT mutation. 
All together the results further suggest that PMMST should not be sensitive to targeted 
therapies aiming at BRAF. PMMST appear to be heterogeneous at the molecular level and 
appear in our series to be associated with CCND1 amplification and NRAS mutations. Further 
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studies are needed to determine whether cases associated with NRAS or KIT mutations or 
CCND1 amplifications may benefit from specific targeted therapies, together with the 
identification of new oncogenes in cases where no specific alterations could be identified. 
Also, longitudinal studies are needed to determine whether these molecular abnormalities 
have prognostic implications. 
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Legend of Figures 
 
Figure 1. Immunohistochemical results. 
A and B, Melan-A staining in case 17 shows a significant staining of neoplastic cells in both 
the in situ (A), and the invasive (B) components, with a strong and diffuse expression. The 
invasive components is mostly composed of sheets of spindle cells; C and D, C-Kit receptor is 
expressed in the majority of the neoplastic, morphologically undifferenciated cells in case 10, 
both by in situ (C) and invasive (D) cells; E and F, Representative cyclin-D1 immunostainings 
showing a strong nuclear expression by in situ and invasive components of case 17 (E) and 14 
(F), respectively. 
 
Figure 2. CCND1 FISH analysis using split signal FISH DNA probes. 
A high copy number of the CCND1 gene, with more than 10 signals per nuclei, can be 
evidenced in the majority (over 70% of cells) of neoplastic cells from cases 11 (A) and 4 (B). 
 
Figure 3. Somatic mutations in sinonasal melanoma. 
Chromatograms showing the following mutated genes: KIT (A), BRAF (B), and NRAS (C, D). 
Sequences are shown above the chromatograms, arrows indicate the substitutions, the wild-
type amino acids are in black and the mutated one in red.  
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Table 1. Sequences of primers for gene mutation and amplification studies 
Primer name Primer sequence (5’->3’) Hybridization 
temperature 
PCR 
fragment 
size 
(M) BRAF exon 11 F TCCCTCTCAGGCATAAGGTAA 55 °C 313 bp 
(M) BRAF exon 11 R CGAACAGTGAATATTTCCTTTGAT 55 °C 
(M) BRAF  exon 15 F TCATAATGCTTGCTCTGATAGGA 55 °C 224 bp 
(M) BRAF  exon 15 R GGCCAAAAATTTAATCAGTGCA 55 °C 
(M) NRAS  exon 2 F GAACCAAATGGAAGGTCACA 55 °C 301 bp 
(M) NRAS  exon 2 R TGGGTAAAGATGATCCGACA 55 °C 
(M) NRAS  exon 3 F GGTGAAACCTGTTTGTTGGA 55 °C 272 bp 
(M) NRAS exon 3 R AACCTAAAACCAACTCTTCCCA 55 °C 
(M) KIT exon 11 F GATCTATTTTTCCCTTTCTC 55 °C 174 bp 
(M) KIT exon 11 R AGCCCCTGTTTCATACTGAC 55 °C 
(M) KIT exon 13 F CATCAGTTTGCCAGTTGTGC 55 °C 295 bp 
(M) KIT exon 13 R AGCAAGAGAGAACAACAGTCTGG 55 °C 
(M) KIT exon 17 F TCATTCAAGGCGTACTTTTG 55 °C 350 bp 
(M) KIT exon 17 R TCGAAAGTTGAAACTAAAAATCC 55 °C 
(M) KIT exon 18 F CATTTCAGCAACAGCAGCAT 60 °C 287 bp 
 
76 bp 
 
94 bp 
 
69 bp 
 
63 bp 
 
65 bp 
 
62 bp 
 
59 bp 
 
(M) KIT exon 18 R 
(A) ACTIN F 
(A) ACTIN R 
(A) GADPH F 
(A) GADPH R 
(A) KIT F 
(A) KIT R 
(A) MDM2 F 
(A) MDM2 R 
(A) CDK4 F 
(A) CDK4 R 
(A) CCDN1 F 
(A) CCDN1 R 
(A) MITF F 
(A) MITF R 
CAAGGAAGCAGGACACCAAT 
CATGGTGCATCTCTGCCTTACA 
ACAGCCTGGATAGCAACGTACA 
GCCCCCGGTTTCTATAAATTG 
CTGGCGACGCAAAAGAAGAT 
TCCTCAAACAGGCATAGATTTCC 
TGTGGATAGCATGCCTTGGA 
AGGACATCTTATGGCCTGCTTTAC 
GGGCAGGGCTTATTCCTTTT 
ATTGCATCGTTCACCGAGATC 
CTTGACTGTTCCACCACTTGTCA 
CGTGGCCTCTAAGATGAAGGA 
CGGTGTAGATGCACAGCTTCTC 
TGTCACTGATCCACTCCTTTCCT 
TCCGGCTGCTTGTTTTGG 
60 °C 
60 °C 
60 °C 
60 °C 
60 °C 
60 °C 
60 °C 
60 °C 
60 °C 
60 °C 
60 °C 
60 °C 
60 °C 
60 °C 
60 °C 
 
Abbreviations : F, forward; R, reverse; bp, base pair, M, primer used for mutation studies; A, 
primer used for amplification studies 
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Table 2. Clinical and pathological features 
Case Age/sex Symptoms Site Endocopy 
Size 
(cm) 
Architecturea Cytologyb Pigmentationc Necrosisd 
Mitotic 
ratee 
Inflammationf Stromag 
1 74/F Epistaxis Nasal cavity Polyp 2 S U M 1 24 1,P F 
2 70/F Epistaxis+headache Ethmoïdo-frontal sinus Mass 1,5 S+P S+U H 1 23 0 A 
3 63/F Epistaxis+earache 
Naso-ethmoido-frontal sinuses 
+orbit 
Mass 3 S U 0 3 21 1 A 
4 80/M 
Anosmia+nasal 
obstruction 
Nasal cavity +cavum Mass 4 S R+G M 2 18 0 A 
5 68/F 
Epistaxis+nasal 
obstruction 
Nasal cavity +ethmoid sinus Mass 2,5 S R+G M 3 20 1,T A 
6 78/M Nasal obstruction Ethmoido-maxillary sinus Polyp 1 S U M 0 10 2,T A 
7 58/F Epistaxis Nasal cavity Polyp 2 S R M 1 23 3,T A 
8 97/F Epistaxis Nasal cavity Mass 1 S P 0 3 12 0 A 
9 85/F Epistaxis Nasal cavity Mass ? M E 0 1 18 0 A 
10 88/F Epistaxis Nasal cavity Mass 5,5 S U M 1 28 2,P F 
11 75/F Epistaxis Sphenoidal sinus+orbit Mass 2,5 S P 0 0 12 0 F 
12 80/M Epistaxis Nasal cavity Polyp ? S S+U 0 0 14 0 F 
13 55/F Epistaxis Nasal cavity+ septum Mass 2 S U M 1 36 0 A 
14 66/F  Epistaxis Nasal cavity+ethmoid sinus Mass NA S S+E M 0 15 1 A 
15 64/M NA Nasal cavity NA NA S E M 2 10 1,T A 
16 70/F NA 
Nasal cavity+maxillo-ethmoido-
frontal sinuses 
Mass NA S P M 0 4 0 A 
17 46/M Epistaxis 
Nasal cavity+ethmoid and 
frontal sinuses 
NA NA S+M S M 1 22 0 A 
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 NOTE : The mitotic rate is indicated as the number of mitoses for 10 high power fields. 
 
Abbreviations :  
a
 S, solid; P, péritheliomatous; M, meningothelial; 
b
 U, undifferenciated; S, spindle; R, rhabdoid; P, plasmacytoid; E, epithélioid; G, giant cells; In situ, in situ component; 
c
 melanin; H, hemosiderin; 
d
 0, absent; 1, low; 2, moderated; 3, important; 
e
 P, peritumoral; T, intra-tumoral; Intensity of the inflammatory reaction : 0, absent; 1, low; 2, moderated; 3, important; 
f
 F, Fibrosis; A, absent. 
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Table 3. Mutation analyses of BRAF, NRAS and KIT 
 
Case 
BRAF 
exon 15 
NRAS 
exon 2 
NRAS 
exon 3 
KIT 
exon 11 
KIT 
exon 13 
KIT 
exon 17 
KIT 
exon 18 
1 WT WT WT L576P WT WT WT 
2 WT G12D WT WT WT WT WT 
3 WT G12A WT WT WT WT WT 
4 WT WT WT WT WT WT WT 
5 WT WT WT WT WT WT WT 
6 WT WT WT WT WT WT WT 
7 WT WT WT WT WT WT WT 
8 WT WT WT WT WT WT WT 
9 WT WT WT WT WT WT WT 
10 WT WT WT WT WT WT WT 
11 WT WT WT WT WT WT WT 
14 (in situ) WT WT WT WT WT WT WT 
14 (invasive) WT WT WT WT WT WT WT 
15 WT G12D WT WT WT WT WT 
16 WT WT WT WT WT WT WT 
17 D594G WT WT WT WT WT WT 
 
Abbreviation : WT, wild type 
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Table 4. KIT, CCND1, CDK4, MDM2 and MITF gene copy number assessment and Ckit 
and cyclin D1 protein expression 
Case KIT 
gene 
copy 
number 
cKit 
protein 
in situ 
cKit 
protein 
invasive 
CCND1 
gene copy 
number 
CCND1 
Amplification 
(FISH) 
Cyclin 
D1 
protein 
in situ 
Cyclin D1 
protein 
invasive 
CDK4 
gene 
copy 
number 
MDM2 
gene 
copy 
number 
MITF 
gene 
copy 
number 
1 4 1+ 5+ 1 - - 1+ 3 3 3 
2 3 5+ 0 2 ND 1++ 2++ 3 2 4 
3 2 NE 0 3 ND NE 0 3 2 4 
4 5 NE 1+ 7 + NE 8+++ 4 5 4 
5 3 5++ 0 9 ND 3++ 3+++ 2 1 3 
6 3 3++ 0 3 ND 2++ 5++ 4 3 4 
7 1 NE 0 5 ND NE 0 3 2 3 
8 1 NE  0 4 ND NE 0 2 2 5 
9 2 5+ 0 13 ND 0 1+ 8 4 8 
10 8 5++ 5++ 1 ND 0 0 2 2 3 
11 2 5++ 5+ 12 + 0 0 3 2 3 
12 ND 1+++ 1+++ ND ND ND ND ND ND ND 
14  2 9+++ 9+++ 3 - 5+++ 7+++ 3 2 3 
15 4 0 0 7 + - 1+ 4 4 4 
16 2 NE 5+ 2 - NE 5+++ 3 2 2 
17 1 10+++ 5++ 2 ND 7+++ 8+++ 2 2 2 
 
NOTE : For immunohistochemical analyzes, the proportion of positive cells is expressed as 1 
for 10%, 2 for 20%, up to 10 for 100%, and the staining intensity as + for low, ++ for 
moderate and +++ for high.  
Abbreviations : ND, not done; NE, non evaluable. 
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Figure 1
Click here to download high resolution image
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Figure 2
Click here to download high resolution image
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Figure 3
Click here to download high resolution image
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